

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,528	09/19/2005	Shawn De Frees	040853-01-5126US	3615
43850 7590 01/03/2008 MORGAN, LEWIS & BOCKIUS LLP (SF)			EXAMINER	
2 PALO ALTO	O SQUARE	· · · · · · · · · · · · · · · · · · ·	HEARD, THOMAS SWEENEY	
3000 El Camino Real, Suite 700 PALO ALTO, CA 94306			ART UNIT	PAPER NUMBER
THEO HETO,	0.171,000		1654	
			MAIL DATE	DELIVERY MODE
		•	01/03/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/549,528	DE FREES, SHAWN			
Office Action Summary	Examiner	Art Unit			
	Thomas S. Heard	1654			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period was Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	DN. timely filed m the mailing date of this communication. NED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	action is non-final. nce except for formal matters, p				
Disposition of Claims		,			
4) ⊠ Claim(s) 1-19 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-19 are subject to restriction and/or expressions.	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the drawing(s) be held in abeyance. So ion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date			

Application/Control Number:

10/549,528 Art Unit: 1654

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-17 are drawn to a method of forming a peptide conjugate comprising a covalent linkage between a modifying group and a glycosylated or non-glycosylated peptide, wherein said modifying group is conjugated to the peptide via a glycosyl linking group interposed between and covalently linked to both said peptide and said modifying group, said method comprising: a. contacting a cell with a modified sugar comprising a sugar moiety and at least one modifying group, wherein said modifying group is a member independently selected from the group consisting of a water-soluble polymer, a therapeutic moiety, a detectable label, a biomolecule and a targeting moiety; b. incubating said cell under conditions in which said cell internalizes said modified sugar; c. after step b, intracellularly contacting said modified sugar with a glycosylated or non-glycosylated peptide and a glycosyltransferase for which said modified sugar is a substrate, thereby forming said peptide conjugate.

Group II, claim(s) 18 and 19, drawn to a cell comprising a peptide conjugate, said peptide conjugate comprising: (i) a modifying group and a peptide, wherein said modifying group is linked to said peptide via a glycosyl linking group interposed between and covalently linked to both the peptide and said modifying group; and (ii) said modifying group is a member independently selected from the group consisting of a water-soluble polymer, a therapeutic moiety, a detectable label, and a targeting moiety.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: They are not linked by a special technical feature.

Application/Control Number:

10/549,528 Art Unit: 1654

The expression "special technical feature" refers to those features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. Thus, a feature found in the prior art cannot be considered to be a special technical feature. Because the method is known in the art by reference Gross, Hans Jurgen, "Fluorescent CMP-sialic acids as a toll to study the specificity of the CMP-sialic acid carrier and the glycoconjugate sialylation in permeabilized cells, Eur. J. Biochem, 203, 269-275 (1992), it cannot be considered a special technical feature.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Protein to be modified, the modified sugar (i.e., therapeutic agent, water-soluable polymer, detectable label, biomolecule, or targeting moiety with al R groups defined), and cell if Group II is elected.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. That is, Applicant is required to elect a single embodiment wherein all variable are particularly defined. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

10/549,528 Art Unit: 1654 Page 4

The following claim(s) are generic: nearly all.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Pursuant to PCT Rule 13.2 and PCT Administrative Instructions, Annex B, Part 1(f)(l)(B)(2), the species are not artrecognized equivalents.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Thomas S. Heard** whose telephone number is **(571) 272-2064**. The examiner can normally be reached on 9:00 a.m. to 6:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Thomas S. Heard

United States Patent and Trade Office

Remsen 3B21 (571) 272-2064

Art Unit 1654

THE PROOF